Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO.

Centralisation of services
for gynaecological cancers — A Cochrane systematic review. Gynecol Oncol. 2012
Aug;126(2):286–90.
2. Meys EMJ, Kaijser J, Kruitwagen RFPM, Slangen BFM, Van Calster B, Aertgeerts B,
et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A
systematic review and meta-analysis. Eur J Cancer. 2016 May;58:17–29.
3. Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, et al.
Risk of complications in patients with conservatively managed ovarian tumours
(IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Lancet
Oncol. 2019 Mar;20(3):448–58.
4. Alcázar JL, Pascual MA, Graupera B, Aubá M, Errasti T, Olartecoechea B, et al.
External validation of IOTA simple descriptors and simple rules for classifying
adnexal masses. Ultrasound Obstet Gynecol. 2016 Sep;48(3):397–402.
5. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al.
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer,
and stage distribution of detected cancers: results of the prevalence screen of the UK
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009
Apr;10(4):327–40.
6. Buys SS. Effect of Screening on Ovarian Cancer Mortality. JAMA. 2011 Jun
8;305(22):2295.
7. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian
cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016
Mar;387(10022):945–56.
8. Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al.
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from
the International Ovarian Tumor Analysis group. Am J Obstet Gynecol. 2016
Apr;214(4):424–37.
9. Anton C, Carvalho F, Oliveira E, Maciel G, Baracat E, Carvalho J. A comparison of
CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index
(RMI) for the classification of ovarian masses. Clinics. 2012 May 15;67(5):437–41.
10. Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S. Usefulness
of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian
tumors. Arch Gynecol Obstet. 2013 Dec 31;288(6):1377–83.
11. Kaijser J, Vandecaveye V, Deroose CM, Rockall A, Thomassin-Naggara I, Bourne T,
et al. Imaging techniques for the pre-surgical diagnosis of adnexal tumours. Best Pract
Res Clin Obstet Gynaecol. 2014 Jul;28(5):683–95.
12. Coutinho A, Bittencourt LK, Pires CE, Junqueira F, de Oliveira Lima CMA, Coutinho
E, et al. MR Imaging in Deep Pelvic Endometriosis: A Pictorial Essay. RadioGraphics.
2011 Mar;31(2):549–67.
13. PDQ Adult Treatment Editorial Board. Ovarian Epithelial, Fallopian Tube, and
Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version. PDQ
Cancer Information Summaries. 2021.
14. Brett M. R, Jennifer B. P, Thomas A. S, Brett M. R, Jennifer B. P, Thomas A. S.
Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
15. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
16. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin
Oncol Nurs. 2019;35(2):151–6.
17. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian
cancer. Nat Rev Dis Prim. 2016;2:1–22.
18. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019
Mar;393(10177):1240–53.
19. Smith C. A Resident’s Perspective of Ovarian Cancer. Diagnostics. 2017 Apr
27;7(2):24.
20. Foti PV, Attinà G, Spadola S, Caltabiano R, Farina R, Palmucci S, et al. MR imaging
of ovarian masses: classification and differential diagnosis. Insights Imaging. 2016 Feb
16;7(1):21–41.
21. Sohaib SAA. MR imaging in ovarian cancer. Cancer Imaging. 2007;7(Special Issue
A):S119–29.
22. American College of Radiology. Ovarian-Adnexal Reporting & Data System (O-
RADS) [Internet]. Available from: https://www.acr.org/Clinical-Resources/Reporting-
and-Data-Systems/O-Rads
23. Mitchell A, Kwong A, Sekhon S, McGahan JP. Ovarian masses and o-rads: A
systematic approach to evaluating and characterizing adnexal masses with mri. Appl
Radiol. 2021;50(4):7–18.
24. Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS,
Stojanovic S, et al. Ovarian-Adnexal Reporting Data System Magnetic Resonance
Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically
Indeterminate Adnexal Masses. JAMA Netw Open. 2020 Jan 24;3(1):e1919896.
25. American College of Radiology. O-RADS MRI Risk Stratification System. 2020;
26. Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, et al. ESGO/
ISUOG/ IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian
tumors. Ultrasound Obstet Gynecol. 2021 Jul 10;58(1):148–68.